Harpoon Therapeutics Announces Changes to Board of Directors

Joanne Viney, Ph.D., brings expertise as an immunologist and veteran biotech executive to the board

Drs. Luke Evnin and Patrick Baeuerle step down from the Harpoon board

Dr. Baeuerle remains as a scientific advisor to the company

SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of veteran biotech executive Joanne Viney, Ph.D., to its board of directors as an independent board member. Current board members, Luke Evnin, Ph.D, and Patrick Baeuerle, Ph.D., will be stepping down from the board. Following these changes, Harpoon’s board will be composed of nine directors.

“Jo is an accomplished executive with an impressive track record of scientific achievement and drug development,” said Jerry McMahon, Ph.D., President and Chief Executive Officer of Harpoon Therapeutics. “Her expertise as an immunologist will be helpful to the company as we continue to advance our TriTAC T cell engager platform.”

“I am excited to join the board of Harpoon and am looking forward to contributing to the company’s immuno-oncology efforts and impacting the lives of people with cancer,” said Dr. Viney.

Dr. Viney is an entrepreneurial scientist and experienced biotech executive with deep autoimmune and inflammatory disease expertise. Dr. Viney currently serves as President, CSO and Co-founder of Pandion Therapeutics, a privately held startup drug discovery and development company focused on developing modular biologics for regulating autoimmunity and inflammatory disease. Previously, Dr. Viney worked at Biogen where she began as Vice President, Immunology Research and was responsible for building and advancing the company’s immunology portfolio before moving on to become Senior Vice President, Drug Discovery and a member of the senior R&D leadership team. Previous roles include Director of Inflammation Research at Amgen as well as Director, Department of Autoimmunity and Inflammation at Immunex. She received a Ph.D. in immunology from the University of London, St. Bartholomew’s Hospital Medical School and a B.Sc. in biophysical science from the University of East London. Dr. Viney is a member of the Board of Directors of Finch Therapeutics and Quench Bio, and is a member of the Scientific Advisory Board for HotSpot Therapeutics.